Krishnamohan Neha

CHIEF FINANCIAL OFFICERKinnate Biopharma Inc. (KNTE) · full profile →Form 4 · filed Apr 5, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
4
1 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 3, 2024Disposed to issuer(D)64K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 3, 2024Disposed to issuer(D)270K0
Apr 3, 2024Disposed to issuer(D)215K0
Apr 3, 2024Disposed to issuer(D)185K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-010431) within minutes of acceptance. Every field above traces to the original document. Verify it directly: